Kailera Therapeutics (KLRA) stock price is $13.27, up 0.45% on the day, as of Nov 13, 2026. It has a market cap of $1.72Bn, and is classified in the Biotechnology industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap1.72 Bn
P/E-4.94
FCF (Yr)-118.12 Mn
ROA (Yr)-34.16
EV to EBIT3.06
Net Income (Yr)-148.96 Mn
Enterprise Value-1.16 Bn
Add ratio to table…
About
Kailera Therapeutics, Inc. is a clinical stage biotechnology company focused on developing obesity therapeutics. The company advances a pipeline of drug candidates that target the glucagon like peptide 1 pathway and related receptors to help people with obesity achieve weight loss. Its most advanced candidate is a once weekly injectable GLP 1 GIP dual agonist called ribupatide which is being evaluated in global Phase 3 trials. The company also pursues an oral formulation of…
Kailera Therapeutics, Inc. is a clinical stage biotechnology company focused on developing obesity therapeutics. The company advances a pipeline of drug candidates that target the glucagon like peptide 1 pathway and related receptors to help people with obesity achieve weight loss. Its most advanced candidate is a once weekly injectable GLP 1 GIP dual agonist called ribupatide which is being evaluated in global Phase 3 trials. The company also pursues an oral formulation of ribupatide a once daily small molecule GLP 1 receptor agonist named KAI 7535 and a once weekly injectable GLP 1 GIP glucagon triple agonist called KAI 4729. These programs are designed to offer options across the treatment journey including injectable and oral routes and varying mechanisms of action.
Kailera Therapeutics does not currently generate revenue from product sales because its candidates are still in clinical development. The company receives cash through its collaboration agreement with Jiangsu Hengrui Pharmaceuticals which includes an upfront payment equity investment and technology transfer fees. Under the agreement Kailera is entitled to milestone payments tied to development regulatory and commercial achievements as well as tiered royalties on net sales of any approved product outside Greater China. Future revenue may also arise from potential licensing of additional metabolic assets from Hengrui or from direct product sales if any candidate receives regulatory approval.
Kailera Therapeutics operates in a competitive obesity treatment market that includes established players such as Novo Nordisk with its semaglutide based product Wegovy and Eli Lilly with its tirzepatide based product Zepbound. Other competitors include Pfizer AstraZeneca and several biotech firms developing GLP 1 based or dual agonist therapies. The company seeks to differentiate itself by pursuing higher potency molecules oral options and treatment strategies aimed at patients with a body mass index of 35 or greater who have not responded adequately to existing therapies. Its pipeline includes once weekly injectable dual and triple agonists as well as once daily oral tablets which could provide advantages in tolerability and dosing convenience. By focusing on the underserved high BMI population and offering both injectable and oral choices Kailera aims to capture a share of the growing obesity drug market.
The company’s future customers will likely include individuals living with obesity who seek effective weight loss treatments health care providers who prescribe these medications and payers such as insurance companies and government health programs that cover obesity therapies. While specific customer names are not disclosed the business model is built around serving patients and the broader health care system. Success will depend on demonstrating superior weight loss and tolerability compared with existing options to gain formulary placement and reimbursement support.
Sector:HealthcareSector rationaleKailera Therapeutics is a clinical-stage biotechnology company developing drug candidates for obesity, such as ribupatide and KAI 7535. Its business model is centered on the discovery and development of pharmaceuticals, with future revenue expected from product sales and royalties in the healthcare market.Industries:BiotechnologyBiotechnologyPrimaryKailera Therapeutics is a clinical-stage biotechnology company developing therapies derived from biological science, specifically GLP-1 GIP dual and triple agonists like ribupatide. Its revenue model currently consists of collaboration payments, technology transfer fees, and potential milestones from Jiangsu Hengrui Pharmaceuticals.PharmaceuticalsPharmaceuticalsSecondaryThe company is also developing KAI 7535, which is described as a once-daily small molecule GLP-1 receptor agonist, fitting the profile of branded pharmaceutical development.Classified using BQ-MICSCIK: 0002096997
Bull & bear
Investment Thesis
▲ Bull case
Kailera Therapeutics is strategically positioned to capture meaningful share in the rapidly expanding obesity therapeutics market, which is projected to reach $150 billion annually by 2030, driven by the success of GLP-1/GIP dual agonists like its lead candidate KAI-9531. The company’s dual-track approach—combining a once-weekly injectable (KAI-9531) and an oral small molecule (KAI-7535)—provides a competitive edge by addressing both patient preference for convenience and the growing demand for non-injectable options, a gap that current market leaders Novo Nordisk and Eli Lilly have yet to fully exploit despite their dominance in injectable therapies. This diversification reduces reliance on a single modality and could allow Kailera to capture patients who discontinue injectables due to side effects or inconvenience, particularly as oral GLP-1 agents gain traction in later-stage trials. With $400 million in early-stage funding secured at launch in October 2024 and an additional $625 million raised through its IPO, Kailera has a substantial cash runway to advance its pipeline through critical milestones, including the initiation of global Phase 3 trials for KAI-9531, which positions the company to avoid the dilutive financing risks that often plague early-stage biotechs. The successful IPO pricing at the top of its marketed range ($16 per share) and a 62.5% first-day pop reflect strong institutional confidence in its pipeline and the obesity market’s long-term growth trajectory, suggesting that the market may be underestimating the near-term value inflection points from its partnership with Jiangsu Hengrui Pharmaceuticals, which has already demonstrated promising mid-stage data in China showing up to 12.1% weight loss at 26 weeks for its oral obesity drug—a result that, while preliminary, validates the scientific foundation of its licensed candidates and de-risks future development.
Kailera Therapeutics is strategically positioned to capture meaningful share in the rapidly expanding obesity therapeutics market, which is projected to reach $150 billion annually by 2030, driven by the success of GLP-1/GIP dual agonists like its lead candidate KAI-9531. The company’s dual-track approach—combining a once-weekly injectable (KAI-9531) and an oral small molecule (KAI-7535)—provides a competitive edge by addressing both patient preference for convenience and the growing demand for non-injectable options, a gap that current market leaders Novo Nordisk and Eli Lilly have yet to fully exploit despite their dominance in injectable therapies. This diversification reduces reliance on a single modality and could allow Kailera to capture patients who discontinue injectables due to side effects or inconvenience, particularly as oral GLP-1 agents gain traction in later-stage trials. With $400 million in early-stage funding secured at launch in October 2024 and an additional $625 million raised through its IPO, Kailera has a substantial cash runway to advance its pipeline through critical milestones, including the initiation of global Phase 3 trials for KAI-9531, which positions the company to avoid the dilutive financing risks that often plague early-stage biotechs. The successful IPO pricing at the top of its marketed range ($16 per share) and a 62.5% first-day pop reflect strong institutional confidence in its pipeline and the obesity market’s long-term growth trajectory, suggesting that the market may be underestimating the near-term value inflection points from its partnership with Jiangsu Hengrui Pharmaceuticals, which has already demonstrated promising mid-stage data in China showing up to 12.1% weight loss at 26 weeks for its oral obesity drug—a result that, while preliminary, validates the scientific foundation of its licensed candidates and de-risks future development.
Kailera Therapeutics faces significant near-term execution risks due to the extended timeline for clinical readouts, with its lead program KAI-9531 not expected to deliver Phase 3 results until 2028, leaving the company vulnerable to shifting market dynamics, competitive pressures, and potential setbacks in its pipeline that could erode investor confidence long before any meaningful revenue generation begins. The obesity drug market, while projected to reach $150 billion annually by 2030, is already dominated by entrenched incumbents Novo Nordisk and Eli Lilly, which possess vast resources, established manufacturing capabilities, and deep relationships with payers and providers—advantages that Kailera, as a pre-revenue startup with no approved products, cannot overcome in the near term, particularly as these giants continue to expand their own pipelines and engage in aggressive pricing strategies to maintain market share. The company’s reliance on licensed candidates from Jiangsu Hengrui Pharmaceuticals introduces additional dependency risks, as any delays, regulatory hurdles, or quality issues in the partnership could jeopardize the development of both KAI-9531 and KAI-7535, especially given that the mid-stage data from China (showing 12.1% weight loss at 26 weeks) may not be directly translatable to global Phase 3 trials due to differences in patient demographics, trial design, or regulatory standards, creating uncertainty about the efficacy and safety profile that will ultimately determine commercial viability. Furthermore, the successful IPO and subsequent 62.5% first-day surge may have already priced in optimistic expectations for the obesity market’s growth, leaving little room for upside if clinical results fail to meet lofty projections, and the company’s high valuation relative to its preclinical and early-stage pipeline increases the risk of a sharp correction should any negative clinical data emerge or if competitors accelerate their own next-generation therapies, such as oral GLP-1 agents from Novo Nordisk or Eli Lilly, which could diminish Kailera’s differentiation and market opportunity before its products even reach the clinic.
Kailera Therapeutics faces significant near-term execution risks due to the extended timeline for clinical readouts, with its lead program KAI-9531 not expected to deliver Phase 3 results until 2028, leaving the company vulnerable to shifting market dynamics, competitive pressures, and potential setbacks in its pipeline that could erode investor confidence long before any meaningful revenue generation begins. The obesity drug market, while projected to reach $150 billion annually by 2030, is already dominated by entrenched incumbents Novo Nordisk and Eli Lilly, which possess vast resources, established manufacturing capabilities, and deep relationships with payers and providers—advantages that Kailera, as a pre-revenue startup with no approved products, cannot overcome in the near term, particularly as these giants continue to expand their own pipelines and engage in aggressive pricing strategies to maintain market share. The company’s reliance on licensed candidates from Jiangsu Hengrui Pharmaceuticals introduces additional dependency risks, as any delays, regulatory hurdles, or quality issues in the partnership could jeopardize the development of both KAI-9531 and KAI-7535, especially given that the mid-stage data from China (showing 12.1% weight loss at 26 weeks) may not be directly translatable to global Phase 3 trials due to differences in patient demographics, trial design, or regulatory standards, creating uncertainty about the efficacy and safety profile that will ultimately determine commercial viability. Furthermore, the successful IPO and subsequent 62.5% first-day surge may have already priced in optimistic expectations for the obesity market’s growth, leaving little room for upside if clinical results fail to meet lofty projections, and the company’s high valuation relative to its preclinical and early-stage pipeline increases the risk of a sharp correction should any negative clinical data emerge or if competitors accelerate their own next-generation therapies, such as oral GLP-1 agents from Novo Nordisk or Eli Lilly, which could diminish Kailera’s differentiation and market opportunity before its products even reach the clinic.